ArticleJournal of Crohn's & colitis2025
Impact of advanced therapies on surgical recurrence following second ileocolic resection in Crohn's disease.
Article in Journal of Crohn's & colitis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimLong-term outcomes and potential benefits of evolved treatment strategies in patients with Crohn's disease (CD) undergoing a second ileocolic resection (second surgery) are not well characterized. This study aimed to evaluate the risk of a third surgery following second surgery in CD patients.
methodThis retrospective cohort study included CD patients undergoing second surgery between 2000-2021 in Amsterdam UMC. Primary outcome was a third surgery due to disease recurrence at the neoterminal ileum. Two cohorts were compared to assess changes over time: C1 (2000-2009) and C2 (2010-2021).
resultsIn total, 110 patients were included (69 women [62.7%]; median age, 39 years [IQR 30-50]). The rates of third surgery were 12.1% at 5-years and 24.9% at 10-years. Use of prophylactic advanced therapies increased over time (C1: 16.4% vs C2: 41.7%, P = .004). However, the 5-year risk of third surgery was similar in both periods (C1: 12.5% vs C2: 11.5%, P = .45). Similarly, there was no statistically significant difference in third surgery risk between patients treated with vs without prophylactic advanced therapies (HR, 0.87 [95% CI, 0.37-2.02]). Most redo surgeries were performed for stricturing disease, even when the first surgery was for a different indication.
conclusionFollowing second surgery, the 5-year third surgery rate is 12.1%, which has remained stable over the past two decades. No statistically significant reduction in third surgery rates were observed in patients receiving prophylactic advanced therapies. This may reflect both the predominantly stricturing disease as indication for redo surgery, which is typically less amenable to medical treatment, and the shorter follow-up in C2.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.